Core Insights - Chiesi Group has entered into an exclusive license agreement with Aliada Therapeutics to advance blood-brain barrier-crossing technology for lysosomal storage disorders, addressing significant unmet medical needs [1][2][3] Company Overview - Chiesi Group is a research-oriented international biopharmaceutical company focused on developing innovative therapeutic solutions in respiratory health, rare diseases, and specialty care [4] - The company has a commitment to improving quality of life and acting responsibly towards the community and environment, legally binding its commitment as a Benefit Corporation in several countries [5] - With 90 years of experience, Chiesi is headquartered in Parma, Italy, and operates 31 affiliates worldwide, employing over 7,500 people [6] Research and Development - The agreement with Aliada Therapeutics builds on an existing research collaboration initiated in August 2023, focusing on enzyme cargoes modified with Aliada's MODEL™ platform to enhance therapeutic delivery across the blood-brain barrier [3] - Chiesi Global Rare Diseases aims to deliver innovative therapies for rare diseases, ensuring equal access for patients and collaborating with the global rare disease community [7]